The finding that ABC- and GC-type DLBCL cells were equally sensitive to the HHT/bortezomib regimen could reflect multiple factors, including the lack of NF-κB-dependent mechanisms underlying interactions between these agents (e.g., MCL-1 down-regulation). This evidence concerns the gene NFKB1 and diffuse large B-cell lymphoma.